Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.aa.com.tr/en/europe/who-criticized-for-contradictory-covid-19-statements/1902436
Saxon, I don't know if this helps or just muddies the water even more but according to the MS website Rebif is self injected under the skin, i.e. sc, for the MS application.
IV can be by injection or drip.
I’ve emailed the author of the article to see if he can maybe answer some questions???
https://www.rcinet.ca/en/2020/07/07/who-halts-certain-covid-19-drug-trials/
Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that the Company will donate supplies of its investigational intravenous (IV) interferon (IFN) beta-1a for 2,000 patients in the World Health Organization's (WHO) Solidarity trial investigating potential COVID-19 treatments.
Dr. Markku Jalkanen, Faron's CEO, said: "We are pleased that the WHO has included IFN beta-1a on its list of priority drugs to be tested against COVID-19, especially the IV form of the drug, which is what we believe critically ill patients need.
Check the rns out. We are in for 2000 treatments of Traumakine,
It's not 2000 doses of interferon to be used any old way.
gk , I think with both WHO and REMAP , WHO in particular , Faron has to get what data it can just from the quantity rather than quality of treatments . As the WHO trial has been made very simple , in order for it to be carried out in basic hospitals across the globe , I doubt Faron will have managed to implement any of their ARDS monitoring kits , or dosing / diagnostics . Maybe on REMAP they have , as they have their own domain , and most hospitals are in the upper tier of quality , mostly in the UK . Farons data will presumably only deal with the I/V patients , although I'm sure they get given it , they will compare theirs with the injected patients in order to re iterate their findings .
I'm not a clinician , so I don't know how it works exactly .
These two trials are adaptive , and both in very condensed timeframes .
As we can all agree on though , the fact that we are still in there can only be a good thing . And the proven fact that I/V is more effective than injected , also bodes well .
After all the data gets looked at , it may well be found that there is a place for both types of delivery , for certain stages or seriousness of the virus , or with certain populations .
Whether they get to test any trial patients for this unique polymorphism ? who knows .
They certainly will on Hibiscus , and that one we can be sure , if it goes ahead , will have each and every one of the important markers measured in the patients .
From one month 3.60 to 2.89 with all the positive news what u guys posting and think if there is a little bad news where this share will go. Why u can’t just keep quite for two weeks
Translated...............
Active substance Interferon beta 1a.
Manufacturer and marketing authorization holder: Biogen Netherlands BV
is this?
REBIF
AVONEX
Vaikuttava aine Beeta 1 a interferoni.
Valmistaja ja myyntiluvan haltija: Biogen Netherlands BV
onko tämä?
https://www.ravimiregister.ee/en/default.aspx?pv=Loendid.ATCPuu&ms=L03AB07
gk , one of the links you posted on Sunday
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR
This has been only one of the Solidarity type trials that i can even see I/V delivery ( listed here along with Subcutaneous )
The IFN B1a is listed as REBIF .
Maybe for trial they can only list one name - and since Traumakine isn't a marketed name ( yet ) , they can't use that . So use the REBIF name as perhaps its being used subcuaneously and intavenously . They are both the same drug , just one is set up for injection delivery and one for I/V ?
I noted that even in the REMAP study , which is I/V only delivery , they still list the drug as REBIF , and that is even mentioned in the REMAP trial protocol document , as Faron have agreed for hospitals to use REBIF , as it is more accessible to be supplied .
If this is true , there must be a way to use REBIF intravenously ?
Either way - any I/V delivery of IFN B1a is our domain , never mind who supplied the drug .
All of the above is just what I seen , so I may have missed something .
But my understanding is that we will unlikely see the name Traumakine on any of these group trials , as it isnt a brand name yet , so they just go with the generic drug name , or the alternative suppliers ( REBIF )
I agree, that would be incredibly helpful!
My guess is that the analysis of the interim data proved that the HIV drugs didn’t work but showed an improvement of some kind when combined with IFN-B1a. Otherwise they wouldn’t have left the website like it is.
They’re probably finalising what they need to do next (which may or may not involve the HIV drugs) and will update it / us when they have agreed it.
My hope is that the Faron team have been close enough to the programme to understand the outstanding issues, hence releasing the paper on administration routes just in time (for the protocol to be adjusted to take it into consideration). I remember it saying something about administration routes being wrongly considered the same in terms of pharmacological effect.
Maybe I’m joining too many dots, we’ll see.
gkb - I was referring to this WHO page...
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
Whilst it doesn’t reference Traumakine directly, we know:
i) Traumakine was included in the Solidarity trial (RNS etc)
ii) The Lopinavir/Ritonavir with Interferon beta-1a arm of Solidarity was the only one with IFN B1a so that must be the one Traumakine was in
iii) From the link above, the WHO Solidarity page states that they have cancelled the Lopinavir/Ritonavir arm but kept the Lopinavir/Ritonavir with Interferon beta-1a arm (in the Treatment options under study section in black background).
I agree it’s opaque, but there is nothing to suggest that Traumakine is no longer part of the study, and if it had been pulled I am pretty sure Faron would have had to issue an RNS.
Don't hold your breath Oil , I emailed them in March ( just to see if they'd reply really , some guff about would they envisage compassionate use of T , and was fast track status still active for T as it was hard to find any data online ) . Never heard back .
I was in one stock last year , they kept moaning about the directors , one guy emailed them as he wanted some straight answers , the director came straight back and agreed to meet him in Costa in Bristol the next day . Bloke had to buy his own coffee , and the director gave him a right earfull . Quite funny , although the company pretty much worthless now , so not sure it did much good .
Email sent! I've asked fro some clarification on Solidarity Trails etc
Standby for response info'...................
Im going to email Faron and ask for some clarification...............
Remap Cap:
Active Comparator: Interferon-ß1a for COVID-19
Patients will receive Interferon-ß1a intended to be active against COVID-19.
Drug: Interferon-ß1a
IFN-ß1a 10 µg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-ß1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Other Name: IFN-ß1a
Still here though......
https://clinicaltrials.gov/ct2/show/NCT02735707?term=remap+cap&draw=2&rank=1
No mention of it here:
https://clinicaltrials.gov/ct2/show/NCT04330690?term=Solidarity&draw=2&rank=1
"Potential for more?"
Hopefully we wont need more... ;)
REMAP-CAP
HIBISCUS
SOLIDARITY
Potential for more?
News needed to steady the ship!
Traumakine is still in the WHO Solidarity trial (IFN-B1a has not been pulled according to WHO website) and REMAP-CAP.
Given that Traumakine’s entry to each of these trials was signalled in separate RNSs, I would expect they would have to release another if Traumakine was pulled from either.
So in this instance I believe no news is good news.
Let's see... based on this interferon on its own will be tested too.
Vergiere said following the development, the DOH will now have “remdesivir plus interferon as the new regimen, vs remdesivir alone (and) vs interferon alone, and standard of care once shipment of interferon arrives.”
https://www.rappler.com/nation/265737-doh-stop-giving-patients-lopinavir-ritonavir-following-experts-advice